Dynavax Technologies Corporation

NASDAQ:DVAX USA Drug Manufacturers - Specialty & Generic
Market Cap
$1.76 Billion
Market Cap Rank
#5703 Global
#3320 in USA
Share Price
$15.50
Change (1 day)
+0.00%
52-Week Range
$9.36 - $15.72
All Time High
$29.70
About

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also devel… Read more

Market Cap & Net Worth: Dynavax Technologies Corporation (DVAX)

Dynavax Technologies Corporation (NASDAQ:DVAX) has a market capitalization of $1.76 Billion ($1.76 Billion) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #5703 globally and #3320 in its home market, demonstrating a 0.10% increase in market value over the past year.

Market capitalization, also known as net worth in stock markets, is calculated by multiplying Dynavax Technologies Corporation's stock price $15.50 by its total outstanding shares 113684064 (113.68 Million).

Dynavax Technologies Corporation Market Cap History: 2015 to 2026

Dynavax Technologies Corporation's market capitalization history from 2015 to 2026. Data shows change from $2.75 Billion to $1.76 Billion (-4.28% CAGR).

Index Memberships

Dynavax Technologies Corporation is a constituent of 4 market indices:

Index Total Market Cap Weight (%) Rank by Market Cap
NASDAQ Health Care
IXHC
$2.24 Trillion 0.07% #155 of 976
NASDAQ Composite
IXIC
$33.26 Trillion 0.00% #673 of 3165
NASDAQ Biotechnology
NBI
$1.54 Trillion 0.10% #100 of 263
S&P Small-Cap 600 Index
SML
$1.35 Trillion 0.12% #325 of 602

Weight: Dynavax Technologies Corporation's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.

Dynavax Technologies Corporation Market Cap to Earnings & Revenue Ratios Timeline

This chart shows how Dynavax Technologies Corporation's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.

Latest Price to Sales (P/S) Ratio

5.24x

Dynavax Technologies Corporation's market cap is 5.24 times its annual revenue

Industry average:
1.01x
Higher than industry average

Latest Price to Earnings (P/E) Ratio

53.16x

Dynavax Technologies Corporation's market cap is 53.16 times its annual earnings

Industry average:
10.29x
Higher than industry average
What These Ratios Tell Investors:
  • Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
  • Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
  • Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
  • Industry comparison provides context for whether the company is valued higher or lower than peers.
Year Market Cap (USD) Revenue (USD) Net Income (USD) P/S Ratio P/E Ratio
2015 $2.75 Billion $4.05 Million -$106.79 Million 678.17x N/A
2016 $449.05 Million $11.04 Million -$112.44 Million 40.66x N/A
2017 $2.13 Billion $327.00K -$95.15 Million 6501.20x N/A
2018 $1.04 Billion $8.20 Million -$158.90 Million 126.89x N/A
2019 $650.27 Million $35.22 Million -$152.60 Million 18.46x N/A
2020 $505.89 Million $46.55 Million -$75.24 Million 10.87x N/A
2021 $1.60 Billion $439.44 Million $76.71 Million 3.64x 20.85x
2022 $1.21 Billion $722.68 Million $293.16 Million 1.67x 4.13x
2023 $1.59 Billion $232.28 Million -$6.39 Million 6.84x N/A
2024 $1.45 Billion $277.25 Million $27.31 Million 5.24x 53.16x

Competitor Companies of DVAX by Market Capitalization

Companies near Dynavax Technologies Corporation in the global market cap rankings as of March 18, 2026.

Key companies related to Dynavax Technologies Corporation by market ranking:

  • Zoetis Inc (NYSE:ZTS): Ranked #423 globally with a market cap of $51.97 Billion USD.
  • Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
  • Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #455 globally with a market cap of $47.47 Billion USD.
  • Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).

Market capitalization comparison (in billions USD)
Rank Company Symbol Market Cap Price
#423 Zoetis Inc NYSE:ZTS $51.97 Billion $118.15
#434 Haleon plc NYSE:HLN $49.87 Billion $10.46
#455 Takeda Pharmaceutical Co. Ltd. PINK:TKPHF $47.47 Billion $30.07
#719 Jiangsu Hengrui Medicine Co Ltd SHG:600276 $28.19 Billion CN¥55.11

Dynavax Technologies Corporation Historical Marketcap From 2015 to 2026

Between 2015 and today, Dynavax Technologies Corporation's market cap moved from $2.75 Billion to $ 1.76 Billion, with a yearly change of -4.28%.

Year Market Cap Change (%)
2026 $1.76 Billion +0.78%
2025 $1.75 Billion +20.44%
2024 $1.45 Billion -8.66%
2023 $1.59 Billion +31.39%
2022 $1.21 Billion -24.38%
2021 $1.60 Billion +216.18%
2020 $505.89 Million -22.20%
2019 $650.27 Million -37.49%
2018 $1.04 Billion -51.07%
2017 $2.13 Billion +373.42%
2016 $449.05 Million -83.65%
2015 $2.75 Billion --

End of Day Market Cap According to Different Sources

On Mar 17th, 2026 the market cap of Dynavax Technologies Corporation was reported to be:

Source Market Cap
Yahoo Finance $1.76 Billion USD
MoneyControl $1.76 Billion USD
MarketWatch $1.76 Billion USD
marketcap.company $1.76 Billion USD
Reuters $1.76 Billion USD

Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.